Terumo Corp Stock Price, News & Analysis

Terumo Health Outcomes has entered a collaboration and co-marketing agreement with Corazon, Inc. to enhance cardiovascular care. This partnership focuses on Terumo's ePRISM® platform, which uses algorithms to predict patient outcomes post-cardiac procedures, allowing for improved treatment planning. The collaboration aims to leverage Corazon's accreditation services and Terumo's technology to deliver individualized data analytics, ultimately improving patient outcomes and reducing healthcare costs. Both companies share a commitment to innovation in healthcare delivery.

MicroVention, a Terumo subsidiary, has announced the first U.S. clinical case of its FRED X Flow Diverter device. This device, which received FDA PMA approval in September 2021, utilizes MicroVention X Technology to reduce thrombogenicity and enhance blood vessel healing. It's the first of several devices featuring this technology aimed at improving neurovascular treatments. Approximately 6.5 million Americans have unruptured brain aneurysms, highlighting the potential market impact of the FRED X device. The device is designed for adult patients with specific types of intracranial aneurysms.

Terumo Medical Corporation (TMC) announced its support for updated guidelines from the ACC, AHA, and SCAI, which classify radial access as Class 1 (Level of Evidence A) for percutaneous coronary intervention (PCI) in acute coronary syndrome and stable ischemic heart disease patients. This endorsement is expected to enhance the adoption of radial access, known for reducing access-site complications, promoting early ambulation, increasing patient satisfaction, and potentially improving financial outcomes. Terumo celebrates its 30-year legacy in radial access innovation and education.

Terumo Blood and Cell Technologies and PhotonPharma have agreed to collaborate on developing Innocell, a new tumor-specific immunotherapy for solid tumors. This partnership aims to expedite the treatment's market entry and includes Terumo's Mirasol Pathogen Reduction Technology in the manufacturing process. The FDA will support PhotonPharma's regulatory submission using Mirasol's Device Master File. This MOU lays the groundwork for further development and commercialization of Innocell, with a focus on triple-negative breast cancer. This collaboration could significantly benefit patients facing cancer.

On July 20, 2021, Terumo Europe and University Medical Center Utrecht (UMC Utrecht) signed a Memorandum of Understanding (MoU) to enhance their collaboration in oncology, particularly in Selective Internal Radiation Therapy (SIRT) for unresectable liver tumors. The partnership aims to improve clinical evidence and education in interventional oncology. Terumo's subsidiary, Quirem Medical, manufactures QuiremSpheres™ and QuiremScout™ for this purpose, showcasing their commitment to advancing cancer care. This MoU reaffirms the shared goal of both parties to innovate and provide better treatment access to cancer patients.

Terumo Medical Corporation announces the launch of its AZUR™ Vascular Plug, a groundbreaking device for occluding peripheral arteries up to 8mm in diameter. This embolization technology is designed for improved clinical outcomes, incorporating a conformable nitinol braid and advanced detachment mechanism for ease of use. Complementing this, the PG Pro™ Peripheral Microcatheter facilitates the delivery of the AZUR Plug. Both devices, exclusively available in the U.S., enhance treatment options for challenging vascular conditions and reflect Terumo's commitment to innovation in medical technology.

Terumo Corporation (TSE: 4543) has pledged an additional USD 1 million to the COVID-19 Solidarity Response Fund for the WHO, marking its second contribution since April 2020. This donation aims to bolster vaccine equity efforts in low-income countries, which have received less than 1% of global vaccine distributions. The fund, over its first year, has mobilized USD 250 million for essential COVID-19 research, treatments, and supplies. Shinjiro Sato, CEO, emphasized the importance of equitable healthcare during these challenging times.

Terumo Blood and Cell Technologies and CSL Plasma have announced a collaboration to develop a new plasma collection platform at CSL Plasma's U.S. collection centers. A clinical trial for the investigational plasmapheresis device commenced in April 2021. The introduction of this platform is contingent on U.S. FDA device clearance, with further details to follow. Plasma collected plays a crucial role in therapies for life-threatening conditions, including immune deficiencies and hemophilia. CSL Plasma operates over 300 centers globally, providing vital therapies to patients.